Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT antibody persistence and booster study in children previously vaccinated in MENACWY-TT-081 PRI
2010-018730-51Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine and Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease (2 arms), sponsored by GSK. Primary endpoint: Persistence of antibodies. Started Jul 2010; status: completed.
02
Drugs
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccineMeningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2010-018730-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018730-51.